Ask AI
ProCE Banner Series

Precision in Practice: A Master Class on PARPi Combinations, Testing Strategies, and Toxicity Management in Metastatic Prostate Cancer

Join us in person or virtually for this Master Class symposium at ASCO GU 2026 where experts will facilitate small group discussions and case reviews to provide insights on optimizing genetic testing, individualizing treatment strategies with PARP inhibitors, monitoring/managing treatment-related adverse events, and understanding the latest relevant emerging data presented at the meeting.

Not an official event of the 2026 ASCO® Genitourinary Cancers Symposium. Not sponsored, endorsed, or accredited by ASCO®, Association for Clinical Oncology, or Conquer Cancer®, the ASCO Foundation.

  AAPA
  | ACPE
  | AMA
  | ANCC
Who Should Attend

This activity is intended for community oncologists, urologists, oncology nurses and nurse practitioners, physician associates, pharmacists, and other healthcare professionals involved in the care and treatment of patients with prostate cancer.

All Events

Precision in Practice: A Master Class on PARPi Combinations, Testing Strategies, and Toxicity Management in Metastatic Prostate Cancer

Upcoming Events

February

26

2026

7:00 PM - 9:00 PM Pacific Time (PT)

In-person

Marriott Marquis San Francisco, 780 Mission Street, San Francisco, California 94103

7:30 PM - 9:00 PM Pacific Time (PT)

Virtual

Topics

Genitourinary cancers

Additional Info

There are no fees required to participate in this activity.

Americans With Disabilities Act
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact Customer Support prior to the live event.

CME/CE Info

Goal Statement
This activity aims to enhance learners’ knowledge and competence in selecting, sequencing, and managing PARP inhibitor-based therapies for metastatic prostate cancer (mPC) through guideline-concordant testing, informed clinical decision-making based on biomarker results, and proactive toxicity mitigation strategies—ultimately improving patient outcomes.

Target Audience
This activity is intended for community oncologists, urologists, oncology nurses and nurse practitioners, physician associates, pharmacists, and other healthcare professionals involved in the care and treatment of patients with prostate cancer.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Incorporate genetic testing workflows in concordance with guideline recommendations for all HRR mutations to identify patients who may benefit from PARP inhibitor-based therapy.
  • Evaluate efficacy, treatment sequencing, and subgroup data from recent trials of PARPi combinations in mPC, and assess their implications across BRCA and non-BRCA HRR mutation populations
  • Formulate patient care plans with PARP inhibitor-based combination regimens for the treatment of patients with mPC, taking into account recent guideline updates for sequencing, expert recommendations, and recent data, including patient subgroup data
  • Employ multidisciplinary strategies for ongoing therapy management to mitigate and manage adverse events associated with PARPi combination regimens, thereby improving quality of life, adherence, and outcomes in patients with mPC
  • Integrate strategies to identify and address barriers to appropriate genetic and biomarker testing for patients with mPC, including testing workflows and the role of the multidisciplinary care team

Accreditation

Joint Accreditation Statement

In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

NCCN designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Professional Development

NCCN designates this educational activity for a maximum of 1.5 contact hours.

Continuing Pharmacy Education

NCCN designates this Application-based continuing education activity for 1.5 contact hours (0.15 CEUs) of continuing education credit. UAN: JA4008196-0000-26-015-L01-P

Type of Activity: Application ​

Upon successfully completing the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Physician Associate Continuing Medical Education

LogoDescription automatically generated

NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.5 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

Disclosure of Conflicts of Interest
It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose all financial relationships they have had in the past 24 months with ineligible companies. The ACCME Standards for Integrity and Independence require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates and discloses to learners all relevant financial relationships. In addition, all content has been reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, is fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing. Full disclosure of faculty relationships will be made prior to the activity. 

Acknowledgement

Provided by

Provided by the National Comprehensive Cancer Network (NCCN) in collaboration with Clinical Care Options, LLC dba Decera Clinical Education.

NCCN

Supporters

Supported by an educational grant from AstraZeneca. Supported through an independent educational grant from Merck & Co., Inc., Rahway, NJ, USA.

AstraZeneca

Merck Sharp & Dohme, LLC

Partners

Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

For customer support please click here.

Mailing Address:

 

Decera Clinical Education
12001 Sunrise Valley Drive
Suite 304
Reston, VA 20191